Danaher Corporation (DHR)
Market Closed
17 Jul, 20:00
$
203. 83
-1.18
-0.5756%
$
144.26B Market Cap
28.65 P/E Ratio
0.2% Div Yield
4.97M Volume
7.58 Eps
$ 205.01
Previous Close Want to track DHR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
DHR closed today lower at $203.83, a decrease of -0.5756% from yesterday's close, completing a monthly increase of 11.6571% or $21.28. Over the past 12 months, DHR stock lost -10.9174%.
DHR pays dividends to its shareholders, with the most recent payment made on Apr 24, 2026. The next announced payment will be in In 1 weeks on Jul 31, 2026 for a total of $0.4.
The last earnings report, released on Apr 28, 2026, missed the consensus estimates by -1.94%. On average, the company has fell short of earnings expectations by -0.5767%, based on the last three reports.
Danaher Corporation has completed 7 stock splits, with the recent split occurring on Oct 02, 2023.
The company's stock is traded on 12 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks | 1 day ago
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
Zacks | 1 day ago
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Zacks | 1 day ago
Danaher Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 17,915 | $4.19M | $3.6M | -$594,357.47 | -14.18% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 2,022 | $511,274.22 | $405,835.62 | -$105,438.6 | -20.62% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 6,592 | $1.8M | $1.32M | -$479,222.9 | -26.59% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 5,978 | $1.06M | $1.2M | $139,921.78 | 13.2% |
| CE Curtis Ellergodt Rothschild Investment LLC | 12,317 | $2.7M | $2.47M | -$226,349.5 | -8.39% |
Danaher Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Patrick Donnelly Citigroup | 34.2 | $5,938.78 | $6,867.43 | $928.65 | 15.64% |
Danaher Corporation (DHR) FAQ
What is the stock price today?
The current price is $203.83.
On which exchange is it traded?
Danaher Corporation is listed on NYSE.
What is its stock symbol?
The ticker symbol is DHR.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.2%.
What is its market cap?
As of today, the market cap is 144.26B.
Has Danaher Corporation ever had a stock split?
Danaher Corporation had 7 splits and the recent split was on Oct 02, 2023.
Danaher Corporation Profile
| Professional Services Industry | Industrials Sector | Rainer Blair CEO | NYSE Exchange | 235851102 CUSIP |
| US Country | 61,000 Employees | 31 Jul 2026 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
Address: 2200 Pennsylvania Avenue, NW
Phone: 202 828 0850
Website: https://www.danaher.com
